Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital

PURPOSE: To describe the tolerability and efficacy of neratinib as a monotherapy and in combination with capecitabine in advanced HER2-positive breast cancer in a real-world setting. METHODS: Patients who received neratinib for advanced HER2-positive at the Royal Marsden Hospital NHS Trust between A...

Descripción completa

Detalles Bibliográficos
Autores principales: Cunningham, Niamh, Shepherd, Scott, Mohammed, Kabir, Lee, Karla A., Allen, Mark, Johnston, Stephen, Kipps, Emma, McGrath, Sophie, Noble, Jillian, Parton, Marina, Ring, Alistair, Turner, Nicholas C., Okines, Alicia F. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382612/
https://www.ncbi.nlm.nih.gov/pubmed/35976513
http://dx.doi.org/10.1007/s10549-022-06703-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382612/
https://www.ncbi.nlm.nih.gov/pubmed/35976513
http://dx.doi.org/10.1007/s10549-022-06703-3

Ejemplares similares